AcuCort AB (publ) (NGM:ACUC)
Sweden flag Sweden · Delayed Price · Currency is SEK
0.7130
-0.0280 (-3.78%)
At close: Jul 7, 2025
-14.10%
Market Cap173.88M
Revenue (ttm)7.93M
Net Income (ttm)-20.31M
Shares Out226.11M
EPS (ttm)-0.18
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume69,440
Average Volume257,047
Open0.7400
Previous Close0.7410
Day's Range0.7110 - 0.7400
52-Week Range0.5540 - 1.2600
Beta1.34
RSI42.64
Earnings DateAug 22, 2025

About AcuCort AB

AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden. [Read more]

Industry Pharmaceutical Preparations
Founded 2006
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol ACUC
Full Company Profile

Financial Performance

In 2024, AcuCort AB's revenue was 7.72 million, an increase of 17.07% compared to the previous year's 6.59 million. Losses were -17.40 million, 27.1% more than in 2023.

Financial Statements

News

There is no news available yet.